期刊文献+
共找到543篇文章
< 1 2 28 >
每页显示 20 50 100
抗痛风药物febuxostat的合成 被引量:12
1
作者 武瑊 王春辉 +1 位作者 李松 郑志兵 《中国药物化学杂志》 CAS CSCD 2008年第4期259-262,共4页
目的合成新型抗痛风药物febuxostat(1)。方法以羟基苯腈为原料,经硫代甲酰化得到对羟基硫代苯甲酰胺(3),3经环合得到2-(4-羟基苯基)-4-甲基-噻唑-5-羧酸乙酯(4),4与乌洛托品反应,得到中间体2-(3-甲酰基-4-羟基苯基)-4-甲基-噻唑-5-羧酸... 目的合成新型抗痛风药物febuxostat(1)。方法以羟基苯腈为原料,经硫代甲酰化得到对羟基硫代苯甲酰胺(3),3经环合得到2-(4-羟基苯基)-4-甲基-噻唑-5-羧酸乙酯(4),4与乌洛托品反应,得到中间体2-(3-甲酰基-4-羟基苯基)-4-甲基-噻唑-5-羧酸乙酯(5),之后再经醚化、氰化、水解得到目标产物(1)。结果与结论中间体及目标化合物的结构经1H-NMR和FAB-MS确证。该合成路线中使用的原料和试剂价廉易得,反应条件温和易控,操作简便。 展开更多
关键词 febuxostat 黄嘌呤氧化酶抑制剂 抗痛风药 合成
暂未订购
Febuxostat对痛风伴高尿酸血症患者的血液流变学和血小板活化功能的影响 被引量:6
2
作者 刘青员 祁广东 陈鑫 《基础医学与临床》 CSCD 2018年第11期1568-1571,共4页
目的探讨febuxostat(非布司他)对痛风伴高尿酸血症患者血液流变学及血小板活化功能的影响。方法选取滨海县人民医院2015年4月至2017年3月收治的痛风伴高尿酸血症患者68例,随机分为对照组(35例)(给予别嘌醇治疗)和观察组(33例)(给予febux... 目的探讨febuxostat(非布司他)对痛风伴高尿酸血症患者血液流变学及血小板活化功能的影响。方法选取滨海县人民医院2015年4月至2017年3月收治的痛风伴高尿酸血症患者68例,随机分为对照组(35例)(给予别嘌醇治疗)和观察组(33例)(给予febuxostat治疗)。比较两组患者的临床疗效、血液流变学变化以及血小板活化功能的变化。结果治疗总有效率,观察组患者高于对照组患者(P<0. 05),与对照组相比,观察组患者在治疗后的血液流变学指标改善和血小板活化功能改善方面均更为明显(P<0. 05)。结论 Febuxostat治疗能有效地降低痛风伴高尿酸血症患者的高尿酸状态,改善患者的血液流变学与血小板活化功能,疗效优于别嘌醇。 展开更多
关键词 febuxostat 别嘌醇 高尿酸血症 痛风 血液流变学 血小板活化功能
暂未订购
The preparation and characteristics of febuxostat SiO2 solid dispersions 被引量:2
3
作者 宋文丁 杜若 +6 位作者 宋平 钟婷 张卫强 赵阳 王超 张烜 张强 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2014年第7期463-470,共8页
In the present research, we selected Sylysia as a porous material and febuxostat(FBT) as model drug to prepare the FBT SiO2 solid dispersions using a solvent evaporation method. We firstly established an HPLC method... In the present research, we selected Sylysia as a porous material and febuxostat(FBT) as model drug to prepare the FBT SiO2 solid dispersions using a solvent evaporation method. We firstly established an HPLC method for determining FBT in our prepared FBT SiO2 solid dispersions. And then, the characteristics of FBT SiO2 solid dispersions were investigated, including differential scanning calorimetry(DSC), powder X-ray diffraction(PXRD), scanning electron microscope(SEM), particle size and distribution. The solubility and dissolution of FBT SiO2 solid dispersion were also evaluated. The results of DSC and PXRD showed that the FBT existed in an amorphous state in FBT SiO2 solid dispersions. The SEM and particle size results indicated that the shape and average particle size of FBT SiO2 solid dispersions was similar to the Sylysia. The solubility and dissolution of FBT in FBT SiO2 solid dispersions were significantly enhanced compared with the pure FBT. In conclusion, we successfully prepared FBT SiO2 solid dispersions to increase the solubility and dissolution rate of the poorly water-soluble FBT. 展开更多
关键词 febuxostat Sylysia Solid dispersion Solubility and dissolution
原文传递
Characteristic dysbiosis in gout and the impact of a uric acid-lowering treatment,febuxostat on the gut microbiota 被引量:8
4
作者 Suxian Lin Tao Zhang +8 位作者 Lingxiao Zhu Kun Pang Saisai Lu Xin Liao Senhong Ying Lixia Zhu Xin Xu Jinyu Wu Xiaobing Wang 《Journal of Genetics and Genomics》 SCIE CAS CSCD 2021年第9期781-791,共11页
Gut dysbiosis is suggested to play a critical role in the pathogenesis of gout.The aim of our study was to identify the characteristic dysbiosis of the gut microbiota in gout patients and the impact of a commonly used... Gut dysbiosis is suggested to play a critical role in the pathogenesis of gout.The aim of our study was to identify the characteristic dysbiosis of the gut microbiota in gout patients and the impact of a commonly used uric acid-lowering treatment,febuxostat on gut microbiota in gout.16S ribosomal RNA sequencing and metagenomic shotgun sequencing was performed on fecal DNA isolated from 38 untreated gout patients,38 gout patients treated with febuxostat,and 26 healthy controls.A restriction of gut microbiota biodiversity was detected in the untreated gout patients,and the alteration was partly restored by febuxostat.Biochemical metabolic indexes involved in liver and kidney metabolism were significantly associated with the gut microbiota composition in gout patients.Functional analysis revealed that the gut microbiome of gout patients had an enriched function on carbohydrate metabolism but a lower potential for purine metabolism,which was comparatively enhanced in the febuxostat treated gout patients.A classification microbial model obtained a high mean area under the curve up to 0.973.Therefore,gut dysbiosis characterizings gout could potentially serve as a noninvasive diagnostic tool for gout and may be a promising target of future preventive interventions. 展开更多
关键词 GOUT Gut microbiota febuxostat METABOLISM Gene sequencing
原文传递
Effects of febuxostat on atrial remodeling in a rabbit model of atrial fibrillation induced by rapid atrial pacing 被引量:2
5
作者 Yong-Yan FAN Feng XU +5 位作者 Chao ZHU Wen-Kun CHENG Jian LI Zhao-Liang SHAN Yang LI Yu-Tang WANG 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2019年第7期540-551,共12页
Background Febuxostat,a novel nonpurine selective inhibitor of xanthine oxidase(XO),may be used in the prevention and management of atrial fibrillation(AF).The purpose of this study was to evaluate the effects of febu... Background Febuxostat,a novel nonpurine selective inhibitor of xanthine oxidase(XO),may be used in the prevention and management of atrial fibrillation(AF).The purpose of this study was to evaluate the effects of febuxostat on atrial remodeling in a rabbit model of AF induced by rapid atrial pacing(RAP)and the mechanisms by which it acts.Methods Twenty-four rabbits were randomly divided into four groups:sham-operated group(Group S),RAP group(Group P),RAP with 5 mg/kg per day febuxostat group(Group LFP),and RAP with 10 mg/kg per day febuxostat group(Group HFP).All rabbits except those in Group S were subjected to RAP at 600 beats/min for four weeks.The effects of febuxostat on atrial electrical and structural remodeling,markers of inflammation and oxidative stress,and signaling pathways involved in the left atrium were examined.Results Shortened atrial effective refractory period(AERP),increased AF inducibility,decreased mRNA levels of Cav1.2 and Kv4.3,and left atrial enlargement and dysfunction were observed in Group P,and these changes were suppressed in the groups treated with febuxostat.Prominent atrial fibrosis was observed in Group P,as were increased levels of TGF-β1,Collagen I,andα-SMA and decreased levels of Smad7 and eNOS.Treatment with febuxostat attenuated these differences.Changes in inflammatory and oxidative stress markers induced by RAP were consistent with the protective effects of febuxostat.Conclusions This study is the first to find that febuxostat can inhibit atrial electrical and structural remodeling of AF by suppressing XO and inhibiting the TGF-β1/Smad signaling pathway. 展开更多
关键词 ATRIAL FIBRILLATION ATRIAL remodeling febuxostat Rapid ATRIAL PACING XANTHINE OXIDASE
暂未订购
Perturbation of Quorum Sensing in <i>Pseudomonas aeruginosa</i>by Febuxostat 被引量:1
6
作者 Hisham Abdel Monem Abbas Wafaa Ezz Elarab Soliman Moutaz Ahamed Shaldam 《Advances in Microbiology》 2018年第8期650-664,共15页
Quorum sensing is a signal-based communication system in bacteria. It is an attractive target because it regulates the production of virulence factors in Pseudomonas aeruginosa. As a result, interference with quorum s... Quorum sensing is a signal-based communication system in bacteria. It is an attractive target because it regulates the production of virulence factors in Pseudomonas aeruginosa. As a result, interference with quorum sensing could result in inhibition of virulence of Pseudomonas aeruginosa with the merit of lack of selective pressure on growth that leads to development of resistance. This study investigated the anti-quorum sensing and anti-virulence activities of febuxostat in Pseudomonas aeruginosa PAO1 strain. At 1/8 MIC of febuxostat, the production of the quorum-sensing regulated violacein pigment of Chromobacterium violaceum CV026 was significantly reduced. Moreover, it markedly reduced pyocyanin, hemolysin, protease and elastase production. Significant inhibitory activities were also found against biofilm, swimming, twitching and swarming motilities. Molecular docking showed the ability of febuxostat to inhibit quorum sensing by competing with the autoinducers to bind with LasR and RhlR receptors. Febuxostat could bind to both receptors by hydrogen bonding and hydrophobic interaction. From the Molecular docking scores, febuxostat is a very promising quorum sensing inhibitor. Febuxostat could also significantly decrease the level of expression of all QS genes LasI, LasR, RhlI, RhlR, PqsA and PqsR that regulate the production of virulene factors as confirmed by qRT-PCR. 展开更多
关键词 febuxostat Pseudomonas AERUGINOSA QUORUM Sensing Virulence Inhibition Molecular Docking
暂未订购
Preparation, optimization and in vitro–in vivo investigation for capsules of the choline salt of febuxostat
7
作者 Xuemei Han Wanpeng Qi +3 位作者 Wenxiang Dong Mengran Guo Panqin Ma Jing Wang 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2016年第6期715-721,共7页
The objective of the present study was to exhibit the enhanced water-solubility and in vivo oral absorption when febuxostat(FXT) became the salt formation of choline. The formation of the choline salt of febuxostat wa... The objective of the present study was to exhibit the enhanced water-solubility and in vivo oral absorption when febuxostat(FXT) became the salt formation of choline. The formation of the choline salt of febuxostat was confirmed by X-ray powder diffraction, infrared spectroscopy analysis and differential scanning calorimetry. The direct filling method was used to develop a capsule formulation. Cellactose 80 was used as the filler due to its good fluidity, while cross-linked polyvinylpyrrolidone(PVPP) and magnesium stearate(MS) were used as the disintegrant and lubricant, respectively. Then the in vitro release of the formulation was carried out in five different dissolution media including HCl solution(pH 1.2),acetate buffer(pH 4.5), phosphate buffer(pH 6.8 and pH 7.2) and water. Evident improvement of release for choline febuxostat(CXT) was presented in water while the dissolution degree was decreased for CXT in the medium of phosphate buffer(pH 6.8) in comparison with FXT. Furthermore, the pharmacokinetics of CXT was studied in rats using UPLC-MS/MS compared with FXT. The data acquired illustrated that AUC0-24 h of CXT and FXT were22,245.96 ± 7342.92 μg·h/l and 12,249.70 ± 2024.04 μg·h/l, respectively. The relative bioavailability of CXT to FXT was about 181.6% and the P value of AUC0-24 h was less than 0.05. It showed significant difference between the two drugs after oral administration. In conclusion, the water-solubility and oral bioavailability were both improved remarkably for the choline salt of febuxostat and choline salinization was proved an effective way to increase the in vivo absorption for FXT. 展开更多
关键词 CHOLINE febuxostat Characterization PREPARATION In VITRO release BIOAVAILABILITY
暂未订购
Febuxostat治疗妇女痛风的效果优于AUopurinol
8
《基础医学与临床》 CSCD 北大核心 2013年第3期381-381,共1页
据美国WebMD医学新闻网(2011-12-15)报道,根据已发表期刊的资料中,回顾性分析参与第3期比较实验222名高尿酸妇女的数据显示,每天80 mg febuxostat降低血清尿酸值低于6.0mg/dL之效果优于每天100、200或300mg的allopurinol。芝加... 据美国WebMD医学新闻网(2011-12-15)报道,根据已发表期刊的资料中,回顾性分析参与第3期比较实验222名高尿酸妇女的数据显示,每天80 mg febuxostat降低血清尿酸值低于6.0mg/dL之效果优于每天100、200或300mg的allopurinol。芝加哥大学Pritzker医学院和武田全球研发小组的Saima Chohan医生等人,比较了痛风患者使用febuxostat、allopurinol和安慰荆的随机控制实验数据进行了事后分析,这些数据共包括了4101名患者,其中226名女性,有4名女性在开始时的血清尿酸值低于8.0mg/dL,所以仅纳入其他222名患者。 展开更多
关键词 febuxostat 痛风患者 ALLOPURINOL febuxostat 妇女 治疗 数据显示 芝加哥大学
暂未订购
Green UHPLC Method for Simultaneous Determination of Febuxostat and Diclofenac in Pharmaceutical Dosage Form and Human Plasma
9
作者 Shimaa A. Mahmoud Amira M. El-Kosasy Fatma A. Fouad 《Journal of Analytical Sciences, Methods and Instrumentation》 2021年第4期29-45,共17页
Eco-friendly Ultra-high-performance liquid chromatography (UHPLC) with green aqueous-organic mobile phase was applied for the simultaneous determination of febuxostat (FEB) and diclofenac (DIC) with the composition of... Eco-friendly Ultra-high-performance liquid chromatography (UHPLC) with green aqueous-organic mobile phase was applied for the simultaneous determination of febuxostat (FEB) and diclofenac (DIC) with the composition of water:ethanol (85:15<span> </span>v/v) utilizing phenomenex Kinetex C<sub>18</sub> column (4.6 × 100 mm 2.6 μm), flow rate 1 ml/min and<b><span> </span></b>UV detection at 280 nm<b><span> </span></b>with linear ranges of 0.4 - 4.0 μg/mL and 0.5 - 5.0 μg/mL for FEB and DIC, respectively. The proposed method was also successfully applied to analyze the two drugs in pharmaceutical dosage form and human plasma. The results obtained were validated and statistically analyzed and found to be in accordance with those given by reported methods. Moreover, the greenness of the developed method is assessed using suitable analytical Eco-Scale and GAPI tools<b><span> </span></b>and comparison with the previously published methods have been carried out to indicate the priority of the proposed method. UHPLC is considered eco-friendly method regarding uses of safe solvents, simple, accurate and short time of analysis. 展开更多
关键词 febuxostat DICLOFENAC Ultra-High-Performance Liquid Chromatography Eco-Scale Green Analytical Procedure Index Tools
暂未订购
其它:04073 Febuxostat在美国申请治疗痛风
10
作者 李燕燕 《国外药讯》 2005年第4期29-29,共1页
武田/Abbott公司的合资企业TAP医药产品公司已经为选择性的黄嘌呤氧化酶抑制剂febuxostat(Ⅰ)在美国提出新药申请,该药用于治疗慢性痛风患者的高尿酸血症(高尿酸水平)。
关键词 febuxostat 美国 申请 治疗痛风 新药 黄嘌呤氧化酶抑制剂
暂未订购
Clinical Efficacy of Febuxostat Combined with Allopurinol in the Treatment of Hyperuricemia Patients
11
作者 ZHU Mengni HOU Lianhua 《外文科技期刊数据库(文摘版)医药卫生》 2021年第6期006-007,共4页
Objective: the experiment will focus on the implementation of drug therapy for patients with hyperuricemia. The research focuses on the analysis of the application results of febuxostat combined with allopurinol. Meth... Objective: the experiment will focus on the implementation of drug therapy for patients with hyperuricemia. The research focuses on the analysis of the application results of febuxostat combined with allopurinol. Methods: the experiment selected patients with hyperuricemia as the main body of the investigation, and the patients admitted from June 2019 to May 2020 were cut off in the time period. The patients were divided into two groups by using the random number method for comparative study, and the changes of 78 patients' conditions were recorded. The patients in the control group were treated with allopurinol, while those in the observation group were treated with febuxostat combined with allopurinol, and the therapeutic effect was analyzed. Results: from the treatment results, the results of serum uric acid, serum creatinine and urea nitrogen levels in the observation group were better than those in the control group, with significant difference (p < 0.05). At the same time, in the estimation of glomerular filtration rate, the indexes of patients in the observation group after 4 weeks and 12 weeks of treatment are better than those in the control group, and the difference is statistically significant. Conclusion: the combination of febuxostat and allopurinol is effective in the treatment of hyperuricemia, and is helpful to improve the related indicators of blood uric acid. The rehabilitation level of the patients is good and has clinical promotion value. 展开更多
关键词 febuxostat ALLOPURINOL HYPERURICEMIA clinical curative effect
暂未订购
EMEA开始审查febuxostat
12
作者 杨绍杰(摘) 《国外药讯》 2007年第5期30-30,共1页
Ipsen公司已递交febuxostat(Ⅰ)用于治疗症状性高尿酸血症的集中欧盟审批申请。如果获得批准,(Ⅰ)将成为40年来首个治疗高尿酸血症的新药,高尿酸血症与痛风有关。(Ⅰ)是一种口服黄嘌呤氧化酶抑制剂,可降低血中的尿酸水平,并... Ipsen公司已递交febuxostat(Ⅰ)用于治疗症状性高尿酸血症的集中欧盟审批申请。如果获得批准,(Ⅰ)将成为40年来首个治疗高尿酸血症的新药,高尿酸血症与痛风有关。(Ⅰ)是一种口服黄嘌呤氧化酶抑制剂,可降低血中的尿酸水平,并阻止痛风病人关节处尿酸晶体的沉积。(Ⅰ)比现有治疗药物别嘌呤(auopurin01)特异性更强,别瞟呤是通过抑制尿酸通路中的一系列酶发挥作用的。 展开更多
关键词 febuxostat 黄嘌呤氧化酶抑制剂 EMEA 高尿酸血症 治疗药物 痛风病人 尿酸水平 症状性
暂未订购
Febuxostat治疗痛风与别嘌醇疗效相仿
13
作者 景新(摘) 《国外药讯》 2008年第12期20-20,共1页
据美国风湿病学会72届科学年会与美国风湿病科医务人员协会43届年会(ACR/ARHP)上宣读的一项Ⅲ期研究,febuxostat(1)40mg在痛风患者中降低尿酸盐的疗效与别嘌醇(Ⅱ)300rag的相仿。
关键词 febuxostat 痛风患者 别嘌醇 疗效 治疗 风湿病学会 医务人员 风湿病科
暂未订购
Febuxostat, a nonpurine selective inhibitor of xanthine oxidase: a promising medical therapy for chronic heart failure? 被引量:1
14
作者 GAO Ling-gen YAO Xiu-ping +4 位作者 ZHANG Lin WEN Dan LUO Fang ZHOU Xian-liang HUI Ru-tai 《Chinese Medical Journal》 SCIE CAS CSCD 2010年第17期2471-2474,共4页
Heart failure is currently one of the most common and most cost-intensive of the chronic diseases The main cause of chronic heart failure (CHF) is the abnormalities of both cardiac contractile performance and myocar... Heart failure is currently one of the most common and most cost-intensive of the chronic diseases The main cause of chronic heart failure (CHF) is the abnormalities of both cardiac contractile performance and myocardial energy metabolism. Elevated levels of reactive oxygen species (ROS) have been proposed to contribute to both of them. Xanthine oxidoreductase (XO) is a major source of ROS in the cardiovascular system. XO inhibitors (XOIs) have been the cornerstone of the clinical management of gout and conditions associated with hyperuricemia for several decades. 展开更多
关键词 febuxostat reactive oxygen species xanthine oxidase inhibitors chronic heart failure signaling pathways
原文传递
补肾活血方联合非布司他治疗尿酸性肾病临床观察
15
作者 季东方 张单华 +1 位作者 陈凯丽 邓伟 《西部中医药》 2026年第2期163-167,共5页
目的:观察补肾活血方联合非布司他治疗脾肾气虚兼血瘀型尿酸性肾病(uric acid nephropathy,UAN)的临床疗效。方法:选取72例脾肾气虚兼血瘀型UAN患者,按随机数字表法分为对照组和治疗组各36例。对照组予非布司他治疗,治疗组在对照组基础... 目的:观察补肾活血方联合非布司他治疗脾肾气虚兼血瘀型尿酸性肾病(uric acid nephropathy,UAN)的临床疗效。方法:选取72例脾肾气虚兼血瘀型UAN患者,按随机数字表法分为对照组和治疗组各36例。对照组予非布司他治疗,治疗组在对照组基础上予补肾活血方治疗,两组均治疗4周。比较两组患者血尿酸(serum uric acid,SUA)、血清肌酐(serum creatinine,SCr)、血尿素氮(blood urea nitrogen,BUN)、白细胞介素1β(Interleukin-1β,IL-1β)、β_(2)微球蛋白(β_(2)-microglobulin,β_(2)-MG)、24 h尿蛋白定量(24-hour urinary protein quantification,24 h UPQ)水平以及中医证候积分和临床疗效。结果:治疗后,两组患者血清SUA、SCr、BUN及IL-1β水平均降低(P<0.01,P<0.05),且治疗组SUA、SCr及IL-1β水平低于对照组(P<0.01,P<0.05);尿液β_(2)-MG、24 h UPQ水平以及中医证候积分均降低(P<0.01,P<0.05);总有效率对照组[69.67%(23/33)]低于治疗组[94.12%(32/34)](P<0.05)。两组患者治疗期间均未见明显不良反应。结论:补肾活血方联合非布司他治疗脾肾气虚兼血瘀型UAN安全可靠,具有肾脏保护作用,可能与降低SUA、IL-1β水平,改善肾功能,减轻炎症反应有关。 展开更多
关键词 尿酸性肾病 炎症反应 补肾活血方 非布司他
暂未订购
痛风丸联合非布司他治疗痛风缓解期(痰浊瘀阻证)患者临床观察
16
作者 马春霞 刘陈 +3 位作者 李红 樊心一 邓秀琴 崔世奎 《山东中医杂志》 2026年第1期42-49,共8页
目的:观察痛风丸联合非布司他治疗痛风缓解期的临床疗效。方法:纳入共60例中医辨证符合痰浊瘀阻证的痛风缓解期患者,采用随机数字表法分为观察组和对照组各30例。对照组采用口服非布司他,观察组采用口服痛风丸联合非布司他,治疗周期12... 目的:观察痛风丸联合非布司他治疗痛风缓解期的临床疗效。方法:纳入共60例中医辨证符合痰浊瘀阻证的痛风缓解期患者,采用随机数字表法分为观察组和对照组各30例。对照组采用口服非布司他,观察组采用口服痛风丸联合非布司他,治疗周期12周。观察治疗期间痛风复发率;治疗前后血尿酸(BUA)水平、炎症指标水平[C-反应蛋白(CRP)、红细胞沉降率(ESR)]、疼痛视觉模拟评分(VAS)、中医证候积分;治疗前后肌骨超声检测痛风石面积、关节积液量变化和关节患侧-健侧的红外热像差值变化。结果:两组治疗后对照组复发率为53.30%,观察组为36.70%,经Log-rank检验差异有统计学意义(P<0.05);BUA、CRP、ESR、VAS和中医证候积分,对照组相对基线改变量较观察组相对基线变化量小,组间差异有统计学意义(P<0.05);与治疗前比较,两组痛风石面积大小、关节积液量和红外热像差值均有改善,且观察组改善更明显;对照组有效率为76.70%,观察组为86.70%,观察组疗效等级优于对照组(P<0.05)。结论:痛风丸联合非布司他治疗痛风缓解期(痰浊瘀阻证)较单纯西药治疗,复发风险更低,并能有效降低血尿酸水平和改善临床症状,且安全性好,有望防治高尿酸血症和预防痛风复发,值得推广。 展开更多
关键词 中药丸剂 痛风丸 痛风缓解期 痰浊瘀阻证 非布司他 复发风险
暂未订购
非布司他联合别嘌醇治疗痛风性关节炎的临床效果研究
17
作者 蔺建新 胡剑威 《中国现代药物应用》 2026年第6期30-33,共4页
目的分析非布司他联合别嘌醇治疗痛风性关节炎的临床效果。方法将120例痛风性关节炎患者作为研究对象,按照患者治疗方法不同分为对照组(60例,采用单一非布司他治疗)、研究组(60例,在非布司他用药基础上联合别嘌醇治疗)。对比两组治疗效... 目的分析非布司他联合别嘌醇治疗痛风性关节炎的临床效果。方法将120例痛风性关节炎患者作为研究对象,按照患者治疗方法不同分为对照组(60例,采用单一非布司他治疗)、研究组(60例,在非布司他用药基础上联合别嘌醇治疗)。对比两组治疗效果、用药后不良反应发生率、尿酸水平、血脂指标水平。结果研究组治疗总有效率96.67%(58/60)高于对照组的75.00%(45/60)(P<0.05)。两组治疗后尿酸水平均相比本组治疗前有明显好转,且治疗1个月后,研究组的尿酸水平较对照组低(P<0.05),但两组治疗2、3个月后的尿酸水平对比无较大差异(P>0.05)。治疗后,两组高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、甘油三酯水平均较本组治疗前改善,且研究组高密度脂蛋白胆固醇(1.35±0.21)mmol/L、低密度脂蛋白胆固醇(1.58±0.36)mmol/L、甘油三酯(1.58±0.33)mmol/L均优于对照组的(1.16±0.16)、(2.05±0.33)、(2.21±0.48)mmol/L(P<0.05)。对照组出现1例肝功能异常,不良反应发生率为1.67%;研究组出现1例肝功能异常和1例消化道症状,不良反应发生率为3.33%。两组不良反应发生率对比无较大差异(P>0.05)。结论非布司他+别嘌醇可以用于痛风性关节炎的治疗,临床症状消失,尿酸水平和血脂指标水平均恢复正常,对改善患者生活质量具有十分重要的意义。 展开更多
关键词 非布司他 别嘌醇 痛风性关节炎 治疗效果
暂未订购
不同剂量非布司他联合枸橼酸钾颗粒治疗高尿酸血症伴痛风性肾结石患者的效果对比
18
作者 杨闯 《中国医学创新》 2026年第6期1-5,共5页
目的:对比不同剂量非布司他联合枸橼酸钾颗粒治疗高尿酸血症伴痛风性肾结石患者的效果。方法:选取上海市嘉定区安亭医院2022年1月—2024年1月420例高尿酸血症伴痛风性肾结石患者作为研究对象,采用随机数字表法分为枸橼酸钾组140例(单独... 目的:对比不同剂量非布司他联合枸橼酸钾颗粒治疗高尿酸血症伴痛风性肾结石患者的效果。方法:选取上海市嘉定区安亭医院2022年1月—2024年1月420例高尿酸血症伴痛风性肾结石患者作为研究对象,采用随机数字表法分为枸橼酸钾组140例(单独予以枸橼酸钾颗粒治疗),低剂量组140例[在枸橼酸钾组的基础上联合低剂量非布司他(40 mg/d)治疗],高剂量组140例[在枸橼酸钾组的基础上联合高剂量非布司他(80 mg/d)治疗]。连续治疗3个月。比较三组患者临床疗效、炎症水平、肾功能、不良反应及预后情况。结果:治疗后,高剂量组总有效率(95.00%)高于低剂量组(74.29%)及枸橼酸钾组(67.86%)(P<0.05)。治疗前,三组患者IL-1β、TNF-α及hs-CRP比较,差异无统计学意义(P>0.05);治疗后,三组患者IL-1β、TNF-α及hs-CRP水平均降低,高剂量组低于低剂量组及枸橼酸钾组(P<0.05)。治疗前,三组患者Scr、BUN及血尿酸水平比较,差异无统计学意义(P>0.05);治疗后,三组患者Scr、BUN及血尿酸水平均降低,高剂量组低于低剂量组及枸橼酸钾组(P<0.05)。高剂量组结石复发率低于枸橼酸钾组(P<0.05),高剂量组痛风复发率低于低剂量组及枸橼酸钾组(P<0.05)。三组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:高尿酸血症伴痛风性肾结石患者应用高剂量非布司他联合枸橼酸钾颗粒相较于低剂量非布司他联合枸橼酸钾颗粒及单独使用枸橼酸钾颗粒能有效提高临床疗效,改善炎症水平及肾功能,降低痛风复发率,且安全性较高。 展开更多
关键词 痛风 高尿酸血症 肾结石 非布司他 枸橼酸钾颗粒 炎症水平
暂未订购
Fabrication and Optimization of Febuxostat-loaded Liposomal Gel Using the Box-Behnken Design for Gout Treatment
19
作者 Bhushan Rane Punam Gadekar +2 位作者 Vaibhav Patil Akash Amkar Ashish Jain 《Nano Biomedicine & Engineering》 2024年第3期484-497,共14页
Monosodium urate crystals form and deposit in and around the joints due to hyperuricemia,a condition characterized by a prolonged increase in serum urate levels.This leads to tissue supersaturation with urate and resu... Monosodium urate crystals form and deposit in and around the joints due to hyperuricemia,a condition characterized by a prolonged increase in serum urate levels.This leads to tissue supersaturation with urate and results in gout,a prevalent form of inflammatory arthritis.Gout can be effectively managed with febuxostat(FBT),a nonpurine selective xanthine oxidase inhibitor.Despite the efficacy of FBT,its use is limited by poor oral bioavailability and aqueous solubility,which are influenced by its co-administration with food and enzymatic degradation.To address the formulation challenges,topical liposomal formulations can be utilized.These formulations,which leverage the affinity of liposomes for keratin and their ability to penetrate deeper into the skin,offer improved drug absorption.This study aimed to develop a liposomal formulation with soy lecithin and cholesterol using the thin-film hydration method,optimized via the Box-Behnken design.The optimized liposomal formulation was then incorporated into a transdermal gel prepared with Carbopol 934 using the dispersion method.The optimized liposomal formulation demonstrated favorable properties,including a vesicle size of 392.5±11.02 nm,zeta potential of 28±6.13 mV,polydispersity index of 0.127,and high entrapment efficiency as confirmed via transmission electron microscopy.The resulting transdermal gel exhibited the necessary antibacterial activity;excellent stability;in vitro release of 81.33%±1.19%over 7 h;and appropriate pH,viscosity,spreadability,and gel strength.Overall,the liposomal gel formulation represents a highly effective approach for transdermal drug delivery. 展开更多
关键词 febuxostat(FBT) LIPOSOME transdermal gel Box-Behnken design antimicrobial study
暂未订购
Integrating the Quality-by-Design(QbD)Approach in the Development of Febuxostat-loaded Proniosomal Gel for Topical Delivery
20
作者 Rajeshwar V.Kshirsagar Sujata R.Rajewar +3 位作者 Shreya S.Kokil Matte Kasi Viswanadh Ramling G.Patrakar Datta Maroti Pawde 《Nano Biomedicine & Engineering》 2024年第4期625-637,共13页
Febuxostat(FXT)is useful in treating hyperuricemia and chronic gout.However,it has limited bioavailability orally due to its low solubility and short half-life.This results in the need for more frequent and larger dos... Febuxostat(FXT)is useful in treating hyperuricemia and chronic gout.However,it has limited bioavailability orally due to its low solubility and short half-life.This results in the need for more frequent and larger doses,increasing the likelihood of adverse effects.Against this background,the current study was established to prepare and optimize an FXT-loaded proniosomal gel using the coacervation-phase separation method.A Quality-by-Design(QbD)methodology was used to ensure the quality of the finished product by assessing how critical process parameters and critical material attributes(CMAs)affected the proniosomal gel’s critical quality attributes.Box-Behnken design was employed to explore the effect of CMAs such as the amount of cholesterol,Span 40,and Span 60 on particle size and entrapment efficiency.The optimized proniosomes had a particle size and percentage entrapment efficiency of 193.7±2.26 nm and 85.3%±0.89%,respectively.Scanning electron microscopy was used to examine the surface morphology of the optimized formulation.The developed formulation was also subjected to in vitro drug release and ex vivo permeation studies,which established the efficiency of the prepared proniosomal gel.Stability studies also established the fact that the prepared formulation is stable to variations in temperature for up to 6 months. 展开更多
关键词 febuxostat proniosomal gel Quality-by-Design(QbD) drug delivery
暂未订购
上一页 1 2 28 下一页 到第
使用帮助 返回顶部